Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma

被引：14

作者：

Abeykoon, Jithma P. ^{[1
]}

Vaxman, Julia ^{[1
]}

Patel, Sanjay V. ^{[2
]}

Kumar, Shaji ^{[1
]}

Malave, Gabriella C. ^{[1
]}

Young, Kimberly S. ^{[1
]}

Ailawadhi, Sikander ^{[3
]}

Larsen, Jeremy T. ^{[4
]}

Dispenzieri, Angela ^{[1
]}

Muchtar, Eli ^{[1
]}

Gonsalves, Wilson I. ^{[1
]}

Kourelis, Taxiarchis ^{[1
]}

Leung, Nelson ^{[1
]}

Warsame, Rahma ^{[1
]}

Go, Ronald S. ^{[1
]}

Bergsagel, Leif ^{[1
]}

Lacy, Martha Q. ^{[1
]}

Rajkumar, S. Vincent ^{[1
]}

Gertz, Morie A. ^{[1
]}

Kapoor, Prashant ^{[1
]}

机构：

[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA

[2] Mayo Clin, Dept Ophthalmol, Rochester, MN USA

[3] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL 32224 USA

[4] Mayo Clin, Div Hematol, Scottsdale, AZ USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 199卷 / 01期

关键词：

antibody-drug conjugate; B-cell maturation antigen; monoclonal gammopathy; ANTIBODY; DRUG;

D O I：

10.1111/bjh.18298

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Belantamab mafodotin (BLMF) is a B-cell maturation antigen-directed antibody-drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF-induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively seen patients treated with BLMF outside of trials. Of those, 75% experienced ocular toxicity, with 69% developing keratopathy. Among patients requiring ocular toxicity-related permanent BLMF discontinuation (14%) or dose reduction (11%), 70% had progression of MM within a median of 3 months (95% confidence interval: 0.2-not reached) following BLMF interruption or dose reduction. Ocular toxicity is a major deterrent to the continuous use of BLMF in routine clinical practice. Measures to successfully prevent and mitigate ocular toxicity should be developed to achieve the full potential of this agent.

引用

页码：95 / 99

页数：5

共 50 条

[31] Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial
Popat, Rakesh
Warcel, Dana
O'Nions, Jenny
Cowley, Anna
Smith, Sasha
Tucker, William R.
Yong, Kwee
Esposti, Simona Degli
HAEMATOLOGICA, 2020, 105 (05) : E261 - E263
[32] Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM)
Suvannasankha, Attaya
Kapetanakis, Venediktos
Prawitz, Thibaud
Sarri, Grammati
Hughes, Rachel
Wang, Feng
Hogea, Cosmina
Ferrante, Shannon Allen
Gorsh, Boris
Willson, Jenny
Popat, Rakesh
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S300 - S301
[33] Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients
Lee, Sung-Eun
Jeon, Young-Woo
Yoon, Jae-Ho
Cho, Byung-Sik
Eom, Ki-Seong
Kim, Yoo-Jin
Kim, Hee-Je
Lee, Seok
Cho, Seok-Goo
Kim, Dong-Wook
Lee, Jong Wook
Min, Woo-Sung
Kim, Myungshin
Min, Chang-Ki
THROMBOSIS RESEARCH, 2015, 136 (05) : 974 - 979
[34] The impact of the type of hospital on survival of multiple myeloma patients: The MICORE study
Rios, R.
Gonzalez-Silva, M.
Molina, E.
Garcia-Fernandez, J. R.
Clavero, M. E.
Duran, J. M.
Lopez-Berenguel, F.
Romero, M. M.
Jimenez-Moleon, J. J.
Sanchez, M. J.
Sainz, J.
Jurado, M.
REVISTA CLINICA ESPANOLA, 2013, 213 (07): : 330 - 335
[35] Agent Orange Exposure, Cytogenetics, and Clinical Outcomes in Multiple Myeloma and MGUS Patients
Kulkami, P.
Hall, J. A.
Copeland, L. A.
Nangrani, A.
Dodlapati, J.
JOURNAL OF MILITARY AND VETERANS HEALTH, 2024, 32 (02): : 27 - 33
[36] Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma
Mouhieddine, Tarek H.
Nzerem, Chidimma
Redd, Robert
Dunford, Andrew
Leventhal, Matthew
Sklavenitis-Pistofidis, Romanos
Tahri, Sabrin
El-Khoury, Habib
Steensma, David P.
Ebert, Benjamin L.
Soiffer, Robert J.
Keats, Jonathan J.
Mehr, Shaadi
Auclair, Daniel
Ghobrial, Irene M.
Sperling, Adam S.
Stewart, Chip
Getz, Gad
CANCER RESEARCH COMMUNICATIONS, 2023, 3 (12): : 2560 - 2571
[37] Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients
Greteman, Breanna B.
Tomasson, Michael H.
Kahl, Amanda R.
Wahlen, Madison M.
Bates, Melissa L.
Strouse, Christopher
Charlton, Mary E.
CANCER CAUSES & CONTROL, 2024, : 433 - 442
[38] Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients
Covut, Fahrettin
Driscoll, James Joseph
Cooper, Brenda
Gallogly, Molly
De Lima, Marcos
Malek, Ehsan
LEUKEMIA, 2021, 35 (01) : 250 - 254
[39] Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression
Fernandez de Larrea, Carlos
Isola, Ignacio
Pereira, Arturo
Teresa Cibeira, Ma
Magnano, Laura
Tovar, Natalia
Rodriguez-Lobato, Luis-Gerardo
Calvo, Xavier
Arostegui, Juan I.
Diaz, Tania
Lozano, Ester
Rozman, Maria
Yague, Jordi
Blade, Joan
Rosinol, Laura
LEUKEMIA, 2018, 32 (06) : 1427 - 1434
[40] Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy
Atrash, Shebli
Mammadzadeh, Aytaj
Peng, Fulei
Alkharabsheh, Omar
Afrough, Aimaz
Cui, Wei
Mahmoudjafari, Zahra
Abdallah, Al-Ola
Hashmi, Hamza
CANCERS, 2023, 15 (11)

← 1 2 3 4 5 →